Alpha Thalassemia Genetic Testing
Alpha thalassemia is an autosomal recessive blood disorder caused by a deletion or point mutation in one or more of the alpha globin genes on chromosome 16, which results in a reduction or absence of the alpha globin chain. About ninety percent of cases are due to deletions and the rest are caused by point mutations. Deletions can be on the same (cis) or different (trans) chromosome. Phenotypic presentations range from mild to severe and are dependent on an individual’s specific mutation. The worldwide distribution mirrors that of malaria, suggesting a protective mechanism relationship. Four different types of alpha thalassemia exist:
- Alpha thalassemia silent carrier: a silent hematologic phenotype caused by one mutation of chromosome 16, usually identified after passing the affected gene to offspring.
- Alpha thalassemia trait (alpha thalassemia minor): there may be mild, chronic anemia that does not respond to iron supplementation, with microcytic and hypochromatic RBCs and decrease in mean corpuscular volume (MCV). Caused by two chomosome 16 deletions.
- Hemoglobin H disease: moderate to severe anemia with an enlarged spleen. There is an increase in both beta globin tetramer (HbH) and gamma hemoglobin tetramer (Hemoglobin Barts) and markedly impaired alpha chain synthesis. Clinical presentation is variable and individual dependent, but usually presents in childhood or early adult life. Three hemoglobin alpha genes are affected.
- Non-immune hydrops fetalis syndrome: most severe form of alpha thalassemia in which all four hemoglobin alpha genes are mutated. Often diagnosed in the later months of pregnancy and characterized by hydrops, severe hypochromic anemia, hepatosplenomegaly, hydrocephaly, cardiac defects, pleural and pericardial effusions. All of the hemoglobin is tetrameric hemoglobin gamma chains (Hemoglobin Barts).
Non-deletional alpha-globin point mutations may be pathogenic or benign; either type of mutation may result in an abnormal protein detectable by hemoglobin evaluation. Pathogenic non-deletional point mutations often have a more severe effect than single gene deletions.
Ninety-five percent of alpha-thalassemia is caused by HBA1 and HBA2 gene deletions (point mutations and regulatory gene mutations).
- Diagnosis of Alpha Thalassemia
- Prenatal screening for deletional alpha thalassemia
- Screening of individuals from high-risk populations, such as Mediterranean, Southeast Asian, African, or Middle Eastern descent
- Carrier screening for patients and reproductive partners with a family history of Alpha thalassemia
Negative:
- (αα/αα): No common deletions were detected in the alpha globin gene. Alpha thalassemia risk is decreased, but not excluded.
Positive:
- (--/--): deletion of four alpha globin genes, Bart hydrops fetalis syndrome
- (--/-α): deletion of three alpha globin genes, hemoglobin H disease
- (-α/-α) or (--/αα): deletion of two alpha globin genes, Alpha thalassemia trait
- (-α/αα): deletion of single alpha globin gene, alpha thalassemia silent carrier
No common deletions were detected in the alpha globin gene Alpha thalassemia risk is decreased, but not excluded
Whole blood EDTA (lavender top tube), Amniotic fluid.
Stability (Blood):
- Ambient: 24 hours
- Refrigerated: 3-7 days
5-7 days.
- Orphanet J Rare Dis. 2010 May 28;5:13. [PMID: 20507641]
- Semin Fetal Neonatal Med. 2008 Aug;13(4):215-22. [PMID: 18406222]
- Genet Med. 2011 Feb;13(2):83-8. [PMID: 21381239]
- Lancet. 2012 Jan 28;379(9813):373-83. [PMID: 21908035]
- J Pharm Bioallied Sci. 2012 Jul-Sep; 4(3): 231–235. [PMID: 22617799]